Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by AwareInvestoron Feb 18, 2021 7:31am

233 Views

Post# 32593366

Antibe Therapeutics To Raise $35.1 Million In Bought Deal

Money continues to be raised at a feverish pace in the capital markets, with Antibe Therapeutics the latest firm to announce a significant bought deal financing. The company last night announced that it has entered into an arrangement with Canaccord Genuity to raise $35.1 million in a bought deal financing.

https://thedeepdive.ca/antibe-therapeutics-to-raise-35-1-million-in-bought-deal/

<< Previous

Bullboard Posts

Next >>

Pro Women’s Hockey League comes to NHL 25 in December